Bahrain vs Iran (Islamic Republic of): Percentage of bloodstream infection due to Escherichia coli resistant
Bahrain
63.0%
in 2022
Iran (Islamic Republic of)
70.6%
in 2022
Bahrain rank
9th
Iran (Islamic Republic of) rank
7th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Bahrain
- Iran (Islamic Republic of)
How they compare
Iran (Islamic Republic of) currently reports 70.6% against 63.0% in Bahrain, a difference of 7.6%.
That makes Iran (Islamic Republic of)'s figure about 1.1 times Bahrain's.
Across all 6 years both countries report, Iran (Islamic Republic of) has been ahead every year.
Bahrain ranks 9th and Iran (Islamic Republic of) ranks 7th of 50 countries.
Iran (Islamic Republic of) has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bahrain | Iran (Islamic Republic of) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 49.0% | 75.3% | 26.3% | Iran (Islamic Republic of) |
| 2020s | 59.9% | 70.0% | 10.1% | Iran (Islamic Republic of) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Bahrain or Iran (Islamic Republic of)?
- Iran (Islamic Republic of), at 70.6% against 63.0% in Bahrain as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Bahrain and Iran (Islamic Republic of)?
- 7.6%, with Iran (Islamic Republic of) ahead.
- How many years of comparable data are there for Bahrain and Iran (Islamic Republic of)?
- 6 years are reported by both, from 2017 to 2022.
- How do Bahrain and Iran (Islamic Republic of) rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Bahrain ranks 9th and Iran (Islamic Republic of) ranks 7th of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.